Tim Walbert

传：Tim Walbert is Chairman, President and CEO of Horizon Therapeutics, which he co-founded in 2018. Horizon is a >$25 billion public company (nasdaq: HZNP) focused on the discovery, development and commercialization of medicines that address critical needs for people impacted by rare, autoimmune and severe inflammatory diseases. Prior to joining Horizon, he served as president, chief executive officer and director of IDM Pharma Inc., a public biopharmaceutical company which was acquired by Takeda America Holdings Inc., or Takeda, in 2009. Prior to IDM, Walbert served as executive vice president, commercial operations at NeoPharm Inc., a public biopharmaceutical company. From 2001 to 2005, he served as divisional vice president and general manager, immunology, where he led the global development and launch of the multi-indication biologic HUMIRA and divisional vice president, global cardiovascular strategy at Abbott, now AbbVie. From 1991 to 2001, he held sales and marketing roles with increasing responsibility at G.D. Searle, Merck & Co. Inc. and Wyeth. Walbert received his Bachelor of Arts in business from Muhlenberg College, in Allentown, Pa. He serves as chairman of the board of Chicago based Exicure Inc. and serves on the board of Aurinia Pharmaceuticals Inc., the Illinois Biotechnology Innovation Organization (iBIO), the Biotechnology Innovation Organization (BIO) and the Greater Chicago Arthritis Foundation. He is a member of the National Organization for Rare Disorders (NORD) Business Advisory Board and serves on the Board of Trustees of Muhlenberg College. Mr. Walbert is a member of the Economic Club of Chicago, the Commercial Club of Chicago and the Civic Committee of the Commercial Club of Chicago.